Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAX-10181 plus capecitabine in advanced/metastatic solid tumors
CTR20242270Phase 2Active
- Sponsor
- Guangzhou Zaiji Medical Technology
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MAX-10181 in nasopharyngeal carcinoma (NPC), gastric cancer (GC), Nonhematologic neoplasms, sponsored by Guangzhou Zaiji Medical Technology. Started Sep 2024; status: active.
02
Drugs
MAX-10181
03
Conditions
nasopharyngeal carcinoma (NPC)gastric cancer (GC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20242270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242270.